/ONPPF
ONPPF Stock - Oncopeptides AB (publ)
Healthcare|BiotechnologyOTC
$0.27+0.00%
+$0.00 (+0.00%) • May 5
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.29
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ONPPF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.26 – $0.27
TARGET (TP)$0.30
STOP LOSS$0.24
RISK/REWARD1:1.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.55
52W High$0.27
52W Low$0.27
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $31.65M | $35.22M | $8.36M | $118.30M | N/A |
| Gross Profit | $28.98M | $36.30M | $8.35M | $65.17M | $-14,403,000 |
| Gross Margin | 91.6% | 103.1% | 99.9% | 55.1% | N/A |
| Operating Income | $-283,498,000 | $-253,447,000 | $-349,350,000 | $-1,420,917,000 | $-1,591,279,000 |
| Net Income | $-284,607,000 | $-249,111,000 | $-337,951,000 | $-1,430,317,000 | $-1,594,693,000 |
| Net Margin | -899.3% | -707.3% | -4044.9% | -1209.1% | N/A |
| EPS | $-1.87 | $-2.76 | $-4.11 | $-19.00 | $-25.57 |
Company Overview
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ONPPFBeat Rate
46%
Last 13 quarters
Avg Surprise
-11.8%
EPS vs Estimate
Beats / Misses
6/7
Last 12 quarters
Latest EPS
$-0.28
Q2 2025
EPS Surprise History
Q2 23
+8.1%
$-0.06vs$-0.06
Q3 23
+34.8%
$-0.04vs$-0.06
Q1 24
-29.1%
$-0.09vs$-0.07
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 5, 2025 | — | — | — | — |
Q3 2025 | Aug 21, 2025 | — | — | — | — |
Q2 2025 | May 15, 2025 | — | $-0.28 | — | — |
Q1 2025 | Feb 27, 2025 | — | $-0.04 | — | — |
Q4 2024 | Nov 7, 2024 | — | $-0.04 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.05 | — | — |
Q2 2024 | May 30, 2024 | — | $-0.05 | — | — |
Q1 2024 | Feb 27, 2024 | $-0.07 | $-0.09 | -29.1% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-0.06 | $-0.04 | +34.8% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.06 | $-0.06 | +8.1% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.06 | $-0.08 | -18.8% | ✗ MISS |
Q1 2023 | Feb 16, 2023 | $-0.06 | $-0.10 | -78.5% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.72 | $-1.00 | -38.9% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.87 | $-0.79 | +9.2% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-2.15 | $-1.31 | +39.1% | ✓ BEAT |
Q1 2022 | Feb 17, 2022 | $-3.10 | $-5.23 | -68.7% | ✗ MISS |
Q4 2021 | Nov 24, 2021 | $-4.49 | $-10.33 | -130.1% | ✗ MISS |
Q3 2021 | Aug 19, 2021 | $-4.85 | $-0.32 | +93.4% | ✓ BEAT |
Q2 2021 | May 26, 2021 | $-6.62 | $-3.45 | +47.9% | ✓ BEAT |
Q1 2021 | Feb 18, 2021 | $-6.22 | $-7.59 | -22.0% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ONPPF
What is ONPPF's current stock price?
Oncopeptides AB (publ) (ONPPF) is currently trading at $0.27 per share. The stock has moved +0.00% today.
What is the analyst price target for ONPPF?
No analyst price targets are currently available for this stock.
What sector is Oncopeptides AB (publ) in?
Oncopeptides AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ONPPF's market cap?
Oncopeptides AB (publ) has a market capitalization of $0.06 billion, making it a small-cap company.
Does ONPPF pay dividends?
No, Oncopeptides AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACOGF
Alpha Cognition Inc.
$5.72
Mkt Cap: $0.0B
BSTG
Biostage, Inc.
$4.03
Mkt Cap: $0.1B
DMTTF
Small Pharma Inc.
$0.11
Mkt Cap: $0.0B
HRPMF
Herantis Pharma Oyj
$3.51
Mkt Cap: $0.1B
KDEVF
Karolinska Development AB (publ)
$0.26
Mkt Cap: $0.1B
MCIOF
MCI Onehealth Technologies Inc.
$0.55
Mkt Cap: $0.1B
MSSTF
Mindset Pharma Inc.
$0.54
Mkt Cap: $0.1B
MVRBF
Medivir AB (publ)
$0.82
Mkt Cap: $0.0B
NEVPF
Abliva AB (publ)
$0.03
Mkt Cap: $0.0B
RLFTD
Relief Therapeutics Holding AG
$4.08
Mkt Cap: $0.0B
Explore stocks similar to ONPPF for comparison